TranscriptsUnited KingdomOct 31, 2026, 1:08 PM ETVerici Dx plc (VRCDF) StockSA Transcripts162.75K FollowersVerici Dx plc (VRCDF) Shareholder/Analyst Call October 27, 2026 12:30 PM EDTCompany ParticipantsSara Barrington - CEO & Executive DirectorDavid Anderson - CFO & Company SecretaryPresentationOperatorGood afternoon, ladies and gentlemen. Welcome to the Verici Dx plc investor presentation. [Operator Instructions] The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and will publish those responses where it's appropriate to do so.Before we begin, as usual, we would like to submit the following poll. And if you could give that your kind attention, I'm sure the company would be most grateful.And I would now like to hand you over to CEO, Sara Barrington. Sara, good afternoon.Sara BarringtonCEO & Executive DirectorGood afternoon, everybody, and welcome to this presentation. I'm just going to flip through the disclaimer.I'll just kick off with a reminder that we are, obviously, a kidney transplant diagnostic company. And when we think about diagnostics in transplant, we think about managing the rejection of the organ. But in fact, clinicians have a conundrum in the system, in the patient care pathway, which is actually a bit like seesaw. On the one hand, they're managing kidney rejection. And they do this with the use of very broad, very large drugs called immunosuppression, which basically suppresses the patient's entire immune system. And we all know, from COVID, how scary that can be. And so on the other end of the sea, what they're trying to do is manage the other implications for having no immune system and the toxicity from those drugs, which is, of course, opening up the patient to other conditions, for example, infections or even the onset of oncology and cancer events.Read more current VRCDF analysis and newsView all earnings call transcriptsComments